ClinicalTrials.gg
CompletedNCT05255458Updated Feb 28, 2025

A Study to Evaluate the Long-term Efficacy and Safety of AK102 in Patients With Hyperlipidemia

A Phase 3 interventional study of AK102 and Placebo in Hyperlipidemia, sponsored by Akeso. Completed at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-02-28.

Sponsored by Akeso · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Nov 2021, registered Feb 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
122
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 94 studies in Hyperlipidemias with a site in China — 30 open to participants now, 37 under way, 7 of them phase 3. Hyperlipidemias · China.

Enrollment
44th of 78
122 · median 155
Started
2021
with 5 others
Phase 3
20 of 94
5 open now
Registered
37th of 94
by date
Lead sponsor
3 of 94
Akeso

Among the 94 studies in Hyperlipidemias with a site in China, this one is the 44th largest by enrollment of the 78 interventional ones that give a count, is one of 6 that started in 2021, is one of 20 in phase 3, and was the 37th registered.

Hyperlipidemias

862 studies on the registry are indexed under Hyperlipidemias; 109 are open to participants now.

Browse Hyperlipidemias studies →

Open to participants now

30 of the 94 studies in Hyperlipidemias with a site in China are open now. Recruiting first, the newest first:

25 more — sign in →

All 30 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 67 Hyperlipidemias studies recruiting now, 27 (40%) set no upper age limit and 32 (48%) stop at 75 or younger; 8 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 94 studies in Hyperlipidemias with a site in China, or all of them as a file.
02

Study summary

This is a randomized, double-blind, placebo-controlled phase 3 clinical study evaluating the long-term efficacy and safety of AK102 in patients with primary hypercholesterolemia and mixed hyperlipidemia.

Read the detailed description

This is a Phase 3 clinical study to evaluate the long-term efficacy and safety of AK102, a monoclonal antibody, against proprotein convertase subtilisin/kexin type 9 (PCSK9), in subjects with primary hypercholesterolemia and mixed hyperlipidemia.

03

Conditions studied

  • Hyperlipidemia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject understand and voluntarily sign the written Inform Consent Form (ICF), which must be signed before performing the study procedures.
  2. Male or female patients aged between 18 and 80 years (including upper and lower limits).
  3. The fasting serum LDL-C level of subjects did not meet the treatment goal after at least 4 weeks of stable lipid-lowering background treatment.
  4. Triglyceride ≤ 4.5 mmol/L (400 mg/dl).

Exclusion criteria

Exclusion Criteria:

  1. Homozygous Familial Hypercholesterolemia (HoFH).
  2. Received PCSK9 inhibitors within 6 months before randomization.
  3. Known sensitivity to PCSK9 inhibitors and any substances to be administered.
  4. Severe liver and renal dysfunction.
  5. Previously received organ transplantation.
  6. Uncontrolled hypothyroidism or hyperthyroidism.
  7. Uncontrolled hypertension.
  8. Known hyperlipidemia secondary to comorbidity, including nephrotic syndrome, cholestatic liver failure, etc.
  9. History of of any organ system within the past 5 years.
  10. Pregnant or lactating women.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
122 participants (actual)

Study arms

  • Experimental
    AK102 regimen 1

    Biological: AK102

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • BiologicalAK102

    Administered AK102 by subcutaneous injection Drug: Statins and/or Ezetimibe lipid-lowering therapies

  • DrugPlacebo

    Administered placebo by subcutaneous injection Drug: Statins and/or Ezetimibe lipid-lowering therapies

06

What researchers measure

Primary outcomes

  1. Precentage change from baseline of serum LDL-C level

    Time frame: At week 52

  2. The incidence and severity of adverse events (AE)

    Time frame: Week 0-52

Secondary outcomes

  1. Value and percentage change from baseline of serum TC levels

    Time frame: Week 0-52

  2. Value and percentage change from baseline of serum TG levels

    Time frame: Week 0-52

  3. Value and percentage change from baseline of serum non HDL-C levels

    Time frame: Week 0-52

  4. Value and percentage change from baseline of serum ApoB levels

    Time frame: Week 0-52

  5. Value and percentage change from baseline of serum HDL-C levels

    Time frame: Week 0-52

  6. Value and percentage change from baseline of serum ApoA-I levels

    Time frame: Week 0-52

  7. Value and percentage change from baseline of serum Lp(a) levels

    Time frame: Week 0-52

  8. Evaluate the population pharmacokinetic (PK) characteristics of AK102 , such as AK102 concentration

    Time frame: Week 0-52

  9. Number and percentage of subjects with positive anti-AK102 antibody (ADA) / neutralizing antibody (NAB) and the time of ADA / nab positivity

    Time frame: Week 0-52

07

Study locations

1 site
  • The Third Hospital of Nanchang
    Nanchang, Jiangxi 330009, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2021 to primary completion in Jan 2023, 14 months.

Of 51 industry-sponsored phase 3 interventional studies under Hyperlipidemias, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 14 months is below that.

Counting every sponsor, half of 57 studies reached it within 18 months; a quarter within 11 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2022
First posted
Feb 24, 2022
StartActual
Nov 4, 2021
Primary completionActual
Jan 9, 2023
CompletionActual
Jan 9, 2023
Last update
Feb 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05255458
Lead sponsor
Akeso
Responsible party
Sponsor
First posted
Feb 24, 2022
Start date
Nov 4, 2021
Primary completion
Jan 9, 2023
Completion
Jan 9, 2023
Last update
Feb 28, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ebronucimab

Start the discussion